Actinium Submits CMC Meeting Request to FDA for Iomab-B to Support IND Filing and Anticipated Commencement of Phase 3 Trial in Mid-2015
Actinium Pharmaceuticals, Inc, a New York City-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it has submitted a request for a CMC (Chemistry, Manufacturing and Control) meeting to the U.S. Food and Drug Administration (FDA) for the company's Iomab-B drug candidate currently undergoing preparations for starting the pivotal Phase 3 trial by the middle of 2015. The Company expects to obtain further guidance from the FDA that will allow completion of...
View full press release